BioMarker Strategies has developed two patented core diagnostics technologies to help make precision medicine a reality for patients with solid tumor cancers. The SnapPath(R) Cancer Diagnostics System is the only system that automates and standardizes the ex vivo interrogation of live solid tumor cells. The dynamic information available only from live cells is required (1) to understand initial response to targeted therapies, immunotherapies and combinations; (2) to identify and understand emergent mechanisms of acquired resistance; and (3) to predict individual solid tumor response to treatment. The Company’s PathMAP(R) Functional Signaling Profiles, enabled by SnapPath, represent a new class of highly predictive biomarker tests. BioMarker Strategies has four routes to revenues and scale: Contract Research Services, Out-licensing, a Pipeline of Predictive Tests, and the potential for an FDA Approval Process to bring SnapPath closer to the clinic for use in treatment selection.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
SnapPath Cancer Diagnostics System
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):